IRVING, Texas, May 5, 2026
Caris Life Sciences has announced the launch of Caris MI Clarity™, an advanced AI-powered prognostic test designed to predict both early and late distant recurrence risk in patients diagnosed with HR-positive/HER2-negative, node-negative early-stage breast cancer. The innovative diagnostic solution is the first test developed to provide clinicians with insights into recurrence risk over different phases of disease progression at the time of diagnosis, helping physicians make more informed treatment decisions for postmenopausal breast cancer patients.
AI-Powered Breast Cancer Risk Analysis Enhances Precision Medicine
According to Caris Life Sciences, Caris MI Clarity™ uses advanced artificial intelligence, computational pathology, and machine learning to analyze digitized pathology slides alongside clinical data to assess the likelihood of both early and late distant cancer recurrence. Unlike traditional recurrence assessment tools that typically focus on a single stage of disease progression, the new test provides a broader understanding of how recurrence risk evolves over time.
The company explained that the AI-driven model was trained using Caris’ proprietary multi-modal database containing tens of thousands of breast cancer samples. Researchers used the dataset to identify critical genetic and histologic patterns associated with recurrence risk. The technology was further validated through a major public-private research collaboration involving the ECOG-ACRIN Cancer Research Group, with clinical trial data obtained from the nationally recognized TAILORx and NSABP B-42 studies conducted by NRG Oncology.
Caris stated that the test can typically provide results within three business days after receiving tissue samples, significantly reducing turnaround time compared with conventional testing methods that may require several weeks. The company believes this faster reporting capability could improve treatment planning and support more personalized therapeutic strategies for patients with early-stage breast cancer.
Advertisement
New Prognostic Technology Targets Early and Late Recurrence
The company emphasized that distant recurrence remains one of the primary drivers of breast cancer mortality, making accurate recurrence prediction essential for long-term disease management. In hormone receptor-positive breast cancer, recurrence risk may persist for years after initial diagnosis, with biological factors influencing early recurrence differing from those responsible for recurrence during later stages of disease progression.
Dr. George W. Sledge Jr., Chief Medical Officer at Caris Life Sciences, stated that clinicians have historically faced challenges when attempting to evaluate recurrence risk over different periods using separate testing tools. By combining both early and late recurrence assessments into a single AI-powered diagnostic solution, Caris MI Clarity aims to improve personalized treatment planning while reducing the risks associated with overtreatment or undertreatment.
The company noted that the test delivers separate Low-risk and High-risk classifications for both early recurrence within the first five years and late recurrence occurring between five and fifteen years after diagnosis. The analysis is performed using routine pathology specimens already collected during standard patient care, eliminating the need for additional tissue collection or genomic sequencing procedures.
Caris Expands AI-Driven Oncology Innovation Strategy
The launch of Caris MI Clarity represents another major step in Caris Life Sciences’ expansion into AI-driven precision oncology and multimodal risk assessment technologies. The company continues to integrate next-generation sequencing, machine learning, and computational pathology into diagnostic solutions designed to improve cancer detection, disease monitoring, therapy selection, and clinical decision-making.
Caris stated that its large-scale clinico-genomic database and high-performance computing capabilities allow the company to develop advanced precision medicine technologies capable of addressing the growing complexity of cancer biology. The organization believes AI-powered diagnostics will play an increasingly important role in shaping the future of oncology treatment and personalized patient management across the healthcare industry.
Source: Caris Life Sciences press release
